A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).

Activiteit: Talk or presentation at a conference

Periode26 mrt 2022
EvenementstitelBSN annual meeting
EvenementstypeConference
Mate van erkenningNational